Adrienne's research programme focuses on identifying the genetic alterations involved in the development and progression of bone and soft tissue tumours, and translating the findings into the diagnostic service. Correlation of these abnormalities with the histopathology improves diagnostic accuracy, allows sub-classification of neoplastic disease and helps to predict therapy, and outcome / survival. She identified that brachyury expression is the hallmark of chordoma, a biomarker which is now employed universally in the diagnosis of this tumour; she was the first to report IDH1 and IDH2 mutations in cartilaginous tumours and demonstrated that this mutation was pivotal to the development of Ollier and Maffucci syndrome. She also reported the recurrent H3F3 mutations in giant cell tumour of bone and chondroblastoma. A close collaboration with the Cancer Genome Team in the Wellcome Trust Cancer Institute resulted in the generation of the genomic landscapes of several bone tumour types including chondrosarcoma, osteosarcoma, chordoma, giant cell tumour of bone, and chondroblastoma. Adrienne has worked closely with patients groups to bring about her research.